Cyanogen Bromide

Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes.

Also Known As:

Networked: 108 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Badenhorst, Danelle: 2 articles (12/2004 - 03/2003)
2.	Norton, Gavin R: 2 articles (12/2004 - 03/2003)
3.	Woodiwiss, Angela J: 2 articles (12/2004 - 03/2003)
4.	Acosta, Armando: 1 article (10/2013)
5.	Camacho, Frank: 1 article (10/2013)
6.	Otero, Oscar: 1 article (10/2013)
7.	Reyes, Fátima: 1 article (10/2013)
8.	Sarmiento, María Elena: 1 article (10/2013)
9.	Desser, Sherwin S: 1 article (02/2011)
10.	Koehler, Anne: 1 article (02/2011)

Related Diseases

1.	Cysts 02/01/2011 - "As a first step to characterizing the molecular structure of polar filaments, a polyclonal antiserum was raised in rabbits against a cyanogen bromide-resistant protein extract of mature cysts containing spores of Myxobolus pendula. " 03/01/1980 - "Based upon the criterion of cyanogen bromide reactivity with the modified nucleoside queuosine, the content of queuosine in aspartyl-tRNA of A, castellanii is significantly greater in mature cysts than in trophozoites. "
2.	Neoplasms (Cancer) 01/01/1983 - "This protein behaves similarly to CEA isolated from liver metastases of a colon tumor in its property of being resistant to cleavage by cyanogen bromide. " 01/01/1980 - "A subunit (designated B1) of the tumor associated peptide "Tissue Polypeptide Antigen" (TPA) has been cleaved by cyanogen bromide. " 07/01/1977 - "These studies indicate that chromatography on the acylated DBAE-cellulose matrix, couple with the analytical ion-exchange chromatography of cyanogen bromide treated and untreated amino-acyl-tRNA can be a valuable technique for the determination of alterations in the Q (or Q*) nucleoside content of the tRNAs isolated from normal and tumor tissues." 06/26/2001 - "We have described a drug-responsive form of a cell surface NADH oxidase (hydroquinone oxidase) of cancer cells (tNOX) that exhibits unusual characteristics including resistance to proteases, resistance to cyanogen bromide digestion, and an ability to form amyloid filaments closely resembling those of spongiform encephalopathies and all of which are characteristics of PrP(sc) (PrP(res)), the presumed infective and proteinase K resistant particle of the scrapie prion. "
3.	Osteogenesis Imperfecta (Lobstein Disease) 11/01/1996 - "We have studied a family with autosomal dominant osteogenesis imperfecta (OI) type IV. Electrophoresis of collagen produced by cultured fibroblasts revealed a slower migrating population of collagen I. Cyanogen bromide peptide mapping localised the structural defect to the area of the alpha 1(1)CB3 peptide. " 06/01/1983 - "Analysis of cyanogen bromide peptides of type I collagen from a patient with lethal osteogenesis imperfecta." 09/01/1998 - "The human and canine sequences differed in the location of Y-position proline residues and the presence of two unique canine cyanogen bromide peptides, alpha2 CB3b and alpha2 CB3c,5. Knowledge of the conserved and unique features of canine COL1A2 will be valuable for analysis of the expression, synthesis, and structure of type I collagen as well as studies of canine osteogenesis imperfecta."
4.	Arthritis (Polyarthritis) 03/15/1994 - "To study the T cell determinants of bovine type II collagen (CII) that mediate the autoimmune response in H-2q mice, we have identified a cyanogen bromide fragment of bovine CII, CII(124-402), that induces arthritis in DBA/1 mice. " 06/01/1992 - "This nonapeptide exhibits epitope characteristics and high homology to residues 137-147 of CB11 (a cyanogen bromide fragment of chicken CII, known to contain both arthritis inducing and suppressing determinants). " 02/01/1990 - "The role of autoimmunity to type II collagen in the arthritis of systemic lupus erythematosus (SLE) has been assessed by ELISA and by Western blotting cyanogen bromide cleavage fragments separated on SDS-PAGE. "
5.	Type IV Ehlers-Danlos Syndrome 07/01/1991 - "We have studied a patient with Ehlers-Danlos syndrome type IV. Protein mapping studies of her type III collagen had indicated that cyanogen bromide fragment 9 contained the site of the mutation. " 10/05/1990 - "These losses account for the resistance of EDS-IV collagen to cyanogen bromide and mammalian collagenase digestion. " 08/01/1993 - "Here we have characterised the most amino-terminal glycine substitution so far described in a patient with EDS IV. A combination of peptide mapping and chemical cleavage analysis of cDNA localised the mutation in cyanogen bromide peptide CB5. "

Related Drugs and Biologics

1.	Nucleoside Q (Queuosine)
2.	Transfer RNA (tRNA)
3.	Nucleosides
4.	Peptides (Polypeptides)
5.	Collagen Type II (Type II Collagen)
6.	Proteins (Proteins, Gene)
7.	Epitopes
8.	Collagen Type III (Type III Collagen)
9.	Collagen Type I (Type I Collagen)
10.	Oxidoreductases (Dehydrogenase)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Stem Cell Transplantation
3.	Transplantation
4.	Drug Therapy (Chemotherapy)